Phase I Dose-escalation, Safety / Tolerability and Preliminary Efficacy Study of Intratumoral Administration of GEN0101 in Patients with Advanced Melanoma.
Phase of Trial: Phase I
Latest Information Update: 19 Jan 2017
Price : $35 *
At a glance
- Drugs GEN 0101 (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 17 Jan 2017 Status changed from recruiting to completed.
- 07 Jan 2015 Status changed from not yet recruiting to recruiting, as reported by University Hospital Medical Information Network - Japan
- 19 Mar 2014 New trial record